SpectraCure AB (publ) OMXSTO:SPEC:
Q-PRO® PATENT APPROVED IN JAPAN
Spectracure Q-Pro Patent Approved In Japan
Earlier from SpectraCure
- Spectracure Gets Approval To Commence Clinical Trial
- Spectracure Appoints Johannes Swartling As CEO
- Spectracure Reports Positive Results In Prostate Cancer Study
- SPEC: Clinical progress and new funding strengthen position despite ongoing losses
- SPEC: Q1 2025 saw continued losses and a planned rights issue as SpectraCure advances clinical studies
Later from SpectraCure
- Spectracure Signs Agreement With Cheplapharm For Verteporfin Supply
- Spectracure Says Study Shows Significant PSA Reduction In Prostate Cancer Patients
- Spectracure Q3 Net Loss SEK 35 Mln
- Spectracure To Get SEK 31.3 Mln If All TO5 Warrants Utilized
- Spectracure Signs Agreement With Rostock Hospital For Prostate Cancer Study
Follow SpectraCure into a list and get an email when it puts out news.
Follow SpectraCure